DOXIL/CAELYX

DRUG2 trials

Conditions

AIDS-related Kaposi SarcomaCancerMalignant Female Reproductive System NeoplasmMetastatic Breast CancerMultiple MyelomaOvarian CancerOvarian Epithelial Cancer RecurrentOvarian Tumor

Phase 1

A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer

NCT01715168

Azaya Therapeutics, Inc.Cancer, Malignant Female Reproductive System Neoplasm, Ovarian Cancer +2

Start: 2012-10-31End: 2015-12-31Target: 40Updated: 2015-01-15

Doxil/Caelyx BE Study

CompletedNCT05567601

Baxter Healthcare CorporationAIDS-related Kaposi Sarcoma, Metastatic Breast Cancer, Multiple Myeloma +1

Start: 2023-12-16End: 2024-06-21Updated: 2025-06-05

DOXIL/CAELYX

Sponsors

Conditions

Phase 1